Literature DB >> 11595339

Baclofen attenuates harmaline induced tremors in rats.

M Tariq1, M Arshaduddin, N Biary, K Al Moutaery, S Al Deeb.   

Abstract

Recent experimental and clinical studies clearly suggest the role of gamma-aminobutyric acid (GABA) in the pathogenesis of tremors. The present study was undertaken to investigate the effect of baclofen, a GABA B receptor agonist on harmaline induced tremors. Four groups of female Wistar rats weighing 100+/-15 g were injected with harmaline (10 mg/kg, intraperitoneally) for inducing experimental tremors. The animals in groups 2, 3 and 4 were given baclofen by gavage at doses of 2.5, 5 and 10 mg/kg, respectively, half an hour before harmaline administration, whereas, the rats in group 1 served as control and received water. The latency of onset, intensity and duration of tremor and electromyographic (EMG) responses were recorded. Treatment with baclofen resulted in a dose dependent decrease in the intensity of tremor. Our EMG study also revealed a significant decrease in the amplitude of tremors in baclofen treated rats. A highly significant increase in latency of onset of tremor was observed in the rats treated with high dose (10 mg/kg) of baclofen only. This study clearly suggests beneficial effects of baclofen in harmaline induced tremors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11595339     DOI: 10.1016/s0304-3940(01)02166-8

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  5 in total

Review 1.  Linking Essential Tremor to the Cerebellum: Neurochemical Evidence.

Authors:  Juan Marin-Lahoz; Alexandre Gironell
Journal:  Cerebellum       Date:  2016-06       Impact factor: 3.847

2.  Discriminative stimulus effects of tiagabine and related GABAergic drugs in rats.

Authors:  L M McDonald; W F Sheppard; S M Staveley; B Sohal; F D Tattersall; P H Hutson
Journal:  Psychopharmacology (Berl)       Date:  2008-02-09       Impact factor: 4.530

3.  Harmaline tremor: underlying mechanisms in a potential animal model of essential tremor.

Authors:  Adrian Handforth
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2012-09-12

Review 4.  Current and Future Neuropharmacological Options for the Treatment of Essential Tremor.

Authors:  Hortensia Alonso-Navarro; Elena García-Martín; José A G Agúndez; Félix J Jiménez-Jiménez
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

5.  Functional Antagonism of Sphingosine-1-Phosphate Receptor 1 Prevents Harmaline-Induced Ultrastructural Alterations and Caspase-3 Mediated Apoptosis.

Authors:  Narjes Dahmardeh; Mohammad Shabani; Mohsen Basiri; Taj Pari Kalantaripour; Majid Asadi-Shekaari
Journal:  Malays J Med Sci       Date:  2019-08-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.